Capital One National Association Increases Position in Amgen Inc. (AMGN)
Capital One National Association increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 9.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,778 shares of the medical research company’s stock after buying an additional 2,508 shares during the period. Capital One National Association’s holdings in Amgen were worth $4,968,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Valley National Advisers Inc. raised its stake in Amgen by 4.8% in the second quarter. Valley National Advisers Inc. now owns 714 shares of the medical research company’s stock valued at $109,000 after buying an additional 33 shares during the period. Glassman Wealth Services raised its stake in Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock valued at $110,000 after buying an additional 600 shares during the period. Oakworth Capital Inc. raised its stake in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock valued at $111,000 after buying an additional 100 shares during the period. Nelson Roberts Investment Advisors LLC purchased a new stake in Amgen during the third quarter valued at about $123,000. Finally, Integrated Wealth Management raised its stake in Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock valued at $141,000 after buying an additional 3 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Inc. (NASDAQ:AMGN) traded up 0.64% during mid-day trading on Tuesday, reaching $146.00. 2,934,575 shares of the company traded hands. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $176.85. The company’s 50-day moving average is $151.01 and its 200-day moving average is $160.49. The stock has a market capitalization of $108.61 billion, a price-to-earnings ratio of 14.61 and a beta of 1.15.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.79 by $0.23. Amgen had a return on equity of 29.27% and a net margin of 33.63%. The firm earned $5.81 billion during the quarter, compared to the consensus estimate of $5.73 billion. During the same quarter in the previous year, the company posted $2.72 earnings per share. The business’s revenue was up 1.5% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post $11.56 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 8th. Shareholders of record on Wednesday, November 16th will be given a $1.00 dividend. The ex-dividend date is Monday, November 14th. This represents a $4.00 annualized dividend and a yield of 2.74%. Amgen’s payout ratio is currently 39.92%.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/29/capital-one-national-association-increases-position-in-amgen-inc-amgn.html.
Several equities analysts have commented on the stock. Vetr downgraded shares of Amgen from a “hold” rating to a “sell” rating and set a $166.35 price objective on the stock. in a report on Monday, August 1st. Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $204.00 price objective on shares of Amgen in a report on Thursday, September 8th. Cowen and Company reiterated a “buy” rating on shares of Amgen in a report on Monday, September 19th. Leerink Swann reiterated a “market perform” rating and issued a $163.00 price objective (down from $193.00) on shares of Amgen in a report on Friday, October 28th. Finally, Piper Jaffray Cos. set a $193.00 price objective on shares of Amgen and gave the company a “buy” rating in a report on Thursday, September 15th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $182.04.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.